# Chemotherapy-Induced Peripheral Neuropathy

## Introduction

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common and dose-limiting toxicities of cancer treatment, affecting 30-70% of patients receiving neurotoxic chemotherapy agents. CIPN presents as a predominantly sensory, length-dependent peripheral neuropathy that can significantly impair quality of life and functional capacity. Approximately 30-40% of patients continue to experience symptoms at six months or longer after chemotherapy completion. The pain medicine specialist must understand the agent-specific pathophysiology, the limited prevention options currently available, and the current evidence-based treatment strategies.

## Pathophysiology by Agent Class

### Taxanes (Paclitaxel, Docetaxel)

Taxanes stabilize microtubules by promoting polymerization and preventing depolymerization, disrupting the normal dynamic equilibrium that is essential for axonal transport. This disruption impairs both anterograde and retrograde transport along microtubules, leading to accumulation of cellular debris, mitochondrial dysfunction, and eventual axonal degeneration. Taxanes accumulate in dorsal root ganglion neurons (which lack a blood-nerve barrier), where they cause mitochondrial damage, vacuolization, and neuronal apoptosis. They also trigger neuroinflammation through activation of toll-like receptor 4 (TLR4) on macrophages and satellite glial cells in the DRG, which releases pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6. Clinically, taxane neuropathy is predominantly sensory — numbness, tingling, and burning pain in a stocking-glove distribution — with onset typically after 2-3 cycles. Symptoms may worsen transiently after treatment cessation, a phenomenon known as coasting.

### Platinum Compounds (Cisplatin, Oxaliplatin, Carboplatin)

Cisplatin accumulates in DRG neurons and forms platinum-DNA adducts that cause nuclear and mitochondrial DNA damage, triggering apoptosis. It produces a pure sensory neuronopathy (ganglionopathy) that preferentially affects large myelinated fibers, so loss of proprioception and vibration sense predominate. Ototoxicity often coexists.

Oxaliplatin produces two distinct neuropathy syndromes. The acute neuropathy, which affects more than 90% of patients, consists of cold-triggered paresthesias, dysesthesias, and muscle cramping in the hands, feet, and perioral region within hours of infusion. This is mediated by sodium channel dysfunction — prolonged opening of voltage-gated sodium channels due to oxalate chelation of calcium — and typically resolves within days. The chronic neuropathy is a cumulative dose-dependent sensory neuropathy similar to cisplatin, caused by DRG neuronal apoptosis and becoming dose-limiting beyond cumulative doses of 750-850 mg/m2. Carboplatin is the least neurotoxic platinum compound, causing neuropathy primarily at high cumulative doses.

### Vinca Alkaloids (Vincristine, Vinblastine, Vinorelbine)

Vinca alkaloids bind to tubulin and inhibit microtubule polymerization, disrupting both the mitotic spindle and axonal transport. Vincristine is the most neurotoxic of the group and affects both sensory and motor fibers, causing axonal neuropathy through disrupted axonal transport and Wallerian degeneration. Clinically, early loss of ankle reflexes and distal paresthesias progress to weakness, including foot drop and wrist drop in severe cases. Autonomic neuropathy is common (constipation, urinary retention, orthostatic hypotension), and cranial neuropathies may occur. Cumulative doses above 30-50 mg carry high neuropathy risk.

<image>Comparative illustration of the three major pathophysiological mechanisms of CIPN by agent class: Panel A (Taxanes) shows a microtubule cross-section with paclitaxel molecules stabilizing tubulin polymers, preventing depolymerization, and blocking axonal transport, with an inset showing mitochondrial damage in a DRG neuron; Panel B (Platinum compounds) shows cisplatin entering a DRG neuron through passive diffusion and organic cation transporters, forming platinum-DNA adducts in the nucleus and mitochondria, activating apoptotic pathways; Panel C (Vinca alkaloids) shows vincristine binding to tubulin dimers and preventing microtubule assembly, with disrupted axonal transport and Wallerian degeneration of the distal axon.</image>

| Agent Class | Representative Drugs | Mechanism of Nerve Injury | Neuropathy Type | Distinguishing Feature |
|-------------|---------------------|--------------------------|-----------------|----------------------|
| Taxanes | Paclitaxel, docetaxel | Microtubule stabilization; disrupted axonal transport | Sensory > motor; stocking-glove | Coasting (worsens after cessation) |
| Platinum (cisplatin) | Cisplatin | DRG neuronal apoptosis via DNA adducts | Sensory neuronopathy (ganglionopathy) | Large fiber loss; proprioception/vibration |
| Platinum (oxaliplatin) | Oxaliplatin | Acute: Na+ channel dysfunction; Chronic: DRG apoptosis | Acute cold-triggered + chronic sensory | Cold-triggered paresthesias within hours |
| Vinca alkaloids | Vincristine | Microtubule depolymerization; disrupted transport | Sensory + motor + autonomic | Early areflexia; foot/wrist drop; constipation |
| Proteasome inhibitors | Bortezomib | Mitochondrial apoptosis in DRG | Painful small fiber | SC route reduces risk vs. IV |
| Immunomodulators | Thalidomide, lenalidomide | Anti-angiogenic (vasa nervorum); DRG toxicity | Axonal sensory | Cumulative dose-dependent |
| Checkpoint inhibitors | Nivolumab, pembrolizumab | Autoimmune (GBS-like) | Inflammatory demyelinating | Rare; resembles Guillain-Barre |

### Other Neurotoxic Agents

Bortezomib, a proteasome inhibitor, causes a painful small fiber neuropathy by activating the mitochondrial pathway of apoptosis in DRG neurons and promoting nuclear accumulation of NF-kB. Subcutaneous administration reduces neuropathy risk compared to intravenous delivery. Thalidomide and lenalidomide produce an axonal sensory neuropathy through anti-angiogenic effects on vasa nervorum and direct DRG toxicity, in a cumulative dose-dependent fashion. Eribulin, a microtubule dynamics inhibitor, carries moderate neuropathy risk. Immune checkpoint inhibitors are rarely associated with an inflammatory neuropathy resembling Guillain-Barre syndrome, driven by an autoimmune mechanism.

## Clinical Assessment

### Grading Scales

The NCI-CTCAE (Common Terminology Criteria for Adverse Events) is the most widely used grading system in oncology clinical trials. Grade 1 is asymptomatic with only clinical or diagnostic observations. Grade 2 involves moderate symptoms limiting instrumental activities of daily living. Grade 3 is severe, limiting self-care ADLs. Grade 4 is life-threatening and requires urgent intervention. The Total Neuropathy Score is a comprehensive clinician-rated scale incorporating symptoms, signs, nerve conduction studies, and QST — it is the most sensitive to change but is time-intensive to administer. Patient-reported outcome measures include the EORTC QLQ-CIPN20 (20 items covering sensory, motor, and autonomic symptoms) and the FACT/GOG-Ntx functional assessment.

### Diagnostic Evaluation

Nerve conduction studies show reduced sensory nerve action potential amplitudes in an axonal pattern, with relatively preserved conduction velocities; the sural nerve is most commonly affected. Quantitative sensory testing reveals elevated thermal and vibration detection thresholds. Skin punch biopsy demonstrates reduced IENFD, confirming small fiber involvement, and is useful when nerve conduction studies are normal.

## Prevention Strategies

Prevention of CIPN remains an area of significant unmet need. The ASCO Clinical Practice Guideline (2020 update) provides clear evidence-based recommendations.

### No Agent Recommended for Prevention

No pharmacological agent has sufficient evidence to recommend for routine CIPN prevention. Agents that have been studied without demonstrated benefit include vitamin E, glutamine, glutathione, calcium/magnesium infusions (for oxaliplatin), acetyl-L-carnitine (which may actually worsen neuropathy), amifostine, omega-3 fatty acids, and N-acetylcysteine.

### Dose Modification Strategies

When grade 2 neuropathy develops, reducing the dose of the neurotoxic agent by 25-50% is standard practice. Extending the interval between cycles allows partial nerve recovery. Stop-and-go strategies for oxaliplatin, such as the OPTIMOX approach, alternate between oxaliplatin treatment and maintenance with fluoropyrimidine alone, allowing cumulative dose control without compromising overall survival. Agent substitution — carboplatin for cisplatin, or subcutaneous bortezomib instead of intravenous — can reduce neuropathy risk when oncologically appropriate.

### Cryotherapy and Compression

Surgical glove cryotherapy — wearing frozen gloves and socks during taxane infusions — reduces local drug delivery to peripheral nerves through vasoconstriction. Compression therapy using tight-fitting surgical gloves during infusion mechanically reduces blood flow, and emerging evidence supports its efficacy. Both approaches are practical, low-risk, and increasingly adopted despite the absence of large-scale trial data.

<image>Clinical illustration demonstrating cryotherapy prevention of taxane-induced CIPN, showing a patient during chemotherapy infusion wearing frozen gloves on both hands and frozen booties on both feet. An inset cross-section of a digital artery shows the mechanism: vasoconstriction from cold application reduces local blood flow and chemotherapy drug delivery to the peripheral nerves of the hands and feet, compared to a normal-temperature control showing full blood flow and drug exposure to nerve endings.</image>

## Duloxetine Evidence

Duloxetine is the only pharmacological agent with a moderate recommendation for treatment of established CIPN in the ASCO guidelines. The CALGB 170601 trial (Loprinzi et al., 2013) was a randomized, double-blind, placebo-controlled crossover trial in 231 patients with painful CIPN (primarily oxaliplatin- and paclitaxel-induced). Duloxetine 60 mg/day for five weeks produced a mean pain reduction of 1.06 points on a 0-10 NRS compared to 0.34 for placebo (p = 0.003), and 59% of duloxetine patients reported clinically meaningful pain reduction versus 38% with placebo. Subgroup analysis showed the greatest benefit in oxaliplatin-induced CIPN compared to taxane-induced. Dosing starts at 30 mg/day for one week, then increases to 60 mg/day, with a maximum of 120 mg/day. The mechanism in CIPN involves enhancing descending serotonergic and noradrenergic inhibition and possibly reducing neuroinflammation in the DRG. Limitations include a modest effect size (NNT of approximately 6), side effects including nausea, fatigue, and dry mouth, and potential drug interactions with CYP2D6 substrates (a consideration with tamoxifen).

## Additional Treatment Options

### Pharmacotherapy

Gabapentin and pregabalin are widely used despite limited CIPN-specific RCT evidence, with efficacy extrapolated from other neuropathic pain settings; they represent a reasonable second-line option. Tricyclic antidepressants (nortriptyline, desipramine) have limited CIPN-specific evidence but are useful for comorbid insomnia and depression. Topical agents include lidocaine 5% patches for focal symptoms, topical menthol (1%) which showed benefit in a small RCT, and compounded topical baclofen-amitriptyline-ketamine (BAK) gel. Scrambler therapy (MC5-A Calmare), a surface electrode-based electrocutaneous treatment that delivers "non-pain" information through C-fiber pathways, has shown promising results in small studies and is available at select centers. Acupuncture has a growing evidence base, with multiple RCTs demonstrating modest benefit, and is considered a reasonable option in the ASCO guidelines.

### Rehabilitation

Physical therapy focused on balance and gait training is critical for fall prevention in patients with proprioceptive loss, and strengthening exercises address distal weakness. Occupational therapy provides adaptive strategies for fine motor deficits and assistive devices. Exercise programs involving aerobic exercise and resistance training may improve CIPN symptoms and prevent deconditioning, with several RCTs supporting exercise during and after chemotherapy.

### Emerging Treatments

The high-concentration capsaicin 8% patch, which defunctionalizes TRPV1-expressing nociceptors, is being studied in CIPN-specific trials. Spinal cord stimulation case series in refractory CIPN show pain reduction, and DRG stimulation may offer more targeted relief. Nicotinamide riboside, an NAD+ precursor that addresses mitochondrial dysfunction, has preclinical evidence and clinical trials underway. PARP inhibitors targeting DNA damage repair pathways in DRG neurons are at the preclinical stage. Selective Nav1.7 sodium channel blockers for painful CIPN are in Phase II trials. Photobiomodulation (low-level laser therapy) has emerging evidence from several small positive trials.

## Clinical Pearls

No agent is proven to prevent CIPN; dose modification, cryotherapy, and compression therapy are the most practical preventive strategies available. Duloxetine is the only medication with a moderate evidence-based recommendation for CIPN treatment per the ASCO guidelines and should be started early when neuropathic pain develops. Coasting — worsening neuropathy for weeks to months after chemotherapy cessation — is common with platinum compounds and taxanes, and patients should be counseled that symptoms may transiently worsen before improving. Fall risk assessment is essential in all CIPN patients, particularly those with proprioceptive loss from platinum agents, and referral for balance training and home safety evaluation can prevent serious injuries. The oncology team must be involved in decisions about dose modification, and the pain specialist should communicate CIPN severity and functional impact to inform dose-reduction decisions. Opioids have no role in the routine management of CIPN and should be avoided; neuropathic pain-specific agents are the appropriate first-line approach.

## References

1. Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6):772-781.
2. Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. 2020;38(28):3325-3348.
3. Smith EML, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial (CALGB 170601). JAMA. 2013;309(13):1359-1367.
4. Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941-1967.